Leading Chinese Biotech Firm 3SBio Lays Groundwork For Foray Into Biosimilars In U.S., EU Markets
This article was originally published in The Pink Sheet Daily
Executive Summary
New biologics plant will quadruple the firm's capacity by the end of the year, enabling commercialization of biosimilars in more developed countries and markets, COO says.